Table 2.
Characteristics of included studies and patients
| Study (year) | Country | Data acquisition | No. of patientsa | Age in years (range) | Sex (M/F) | Stage (no.) | FLIPI scored | Treatment regimes (no.) |
|---|---|---|---|---|---|---|---|---|
| Lu et al. [6] (2014) | Australia | Retrospective | 57 | 59b (27–77) | 26/31 | I, 3 II, 7 III, 24 IV, 21 |
0, 2 1, 9 2, 19 3, 11 4, 8 5, 4 Unavailable, 4 |
6× R-CHOP, 57 Additional maintenance R, 45 |
| Luminari et al. [7] (2014) | Italy | Retrospective | 202 | 56b (33–75) | 98/104 | II, 16 III/IV, 186 |
0–2, 131 3–5, 71 |
R-CVP, 66 R-CHOP, 62 R-FM, 74 |
| Zinzani et al. [8] (2013) | Italy | Retrospective | 142 | 63a (25–83) | 55/87 | III, 65 IV, 77 |
NR | R-FM |
| Dupuis et al. [9] (2012) | Multinational | Prospective | 119 | 57b (28–76) | 63/56 | I/II, 8 III/IV, 110 |
0–1, 17 2, 50 3–5, 49 |
6× R-CHOP, 113 2× additional R, 106 |
| Trotman et al. [10] (2011) | Multinational | Prospective | 122 | 57b (26–82) | 67/55 | I/II, 14 III/IV, 108 |
0–1, 28 2, 47 3–5, 47 |
6× R-CHOP + 2× R, 103 8× R-CVP, 19 |
| Le Dortz et al. [11] (2010) | France | Retrospective | 45 | 60a (47–78) | 22/23 | I/II, 5 III, 15 IV, 25 |
0–1, 9 2, 12 3–5, 24 |
6× R-CHOP |
| Bishu et al. [12] (2007) | USA | Retrospective | 16 | NR | NR | II, 3 III, 5 IV, 8 |
NR | CHOP, R-CHOP, CNOP, CVP, R-monotherapy with/without additional RT |
| Zinzani et al. [13] (2007) | Italy | Retrospective | 45 | 55b (31–78) | 25/20 | III/IV, 40 | 2, 28 ≥ 3, 17 |
R-FM or R-CHOP |
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; CNOP cyclophosphamide, mitoxantrone, vincristine, and prednisone; CVP cyclophosphamide, vincristine, and prednisone; FM rituximab, fludarabine, and mitoxantrone; ICE ifosfamide, carboplatin, etoposide; NR not reported; R rituximab; RT radiation therapy
aNumber of patients who were included in this study of whom baseline characteristics were available
bMedian
cMean
dFLIPI score [14]